ABBV stock- Strong area of support that rallied up to the $125s which clearly shows institutional interest within the 94-98 zone.
1-3 risk to reward whilst still keeping an eye on 85s
Reason for opposing catalyst
Retail Investors had all the there chips in hoping for accelerated approval for the drug Rova-T (Drug) which they forked out just shy of $6 billion for Stemcentrx, (Defeating the purpose of the acquisition)
Cut losses quickly
Wait till price action breaches more into the level to buy cheaper